Ozempic / GLP-1

What the lawsuit is about

Lawsuits allege that GLP-1 receptor agonist medications — including Ozempic, Wegovy, Rybelsus, Saxenda, Mounjaro, Zepbound, and Trulicity — can cause gastroparesis (stomach paralysis), ileus, bowel obstruction, and related severe gastrointestinal injuries, and that Novo Nordisk and Eli Lilly did not adequately warn patients and prescribers about those risks.

Defendants dispute the allegations, including causation and the adequacy of their warnings. The medications remain FDA-approved. No page on this site can determine whether a person qualifies for a claim.

Ozempic Lawsuit Update: June 2026

As of June 1, 2026, 3,763 cases were pending in the federal GLP-1 multidistrict litigation (MDL-3094) according to the JPML's monthly statistics report, with roughly 1,200 additional cases reported in coordinated state-court proceedings. The MDL has grown steadily each month since its creation in February 2024. A separate federal proceeding, MDL-3163, consolidates NAION vision-loss claims and held 110 pending actions as of the same report.

The litigation's most important near-term event is the Rule 702 (expert admissibility) hearing window, September 10–18, 2026, set by Case Management Order No. 32, with summary judgment briefing completing August 7, 2026. Bellwether trial dates have not yet been set and are expected to follow those rulings.

Which drugs are included?

Filed cases involve GLP-1 receptor agonists from two manufacturers:

• Novo Nordisk: Ozempic and Rybelsus (semaglutide for type 2 diabetes), Wegovy (semaglutide for weight management), and Saxenda (liraglutide).
• Eli Lilly: Mounjaro and Zepbound (tirzepatide) and Trulicity (dulaglutide).

Both diabetes patients and weight-loss patients appear among filed cases. The medication involved, dose, duration of use, and documented injury all factor into claim review.

Who may qualify for the Ozempic lawsuit?

There is no automatic qualification rule. Claim review commonly considers:

• Documented use of a GLP-1 medication, supported by prescription and pharmacy records.
• A diagnosis such as gastroparesis, ileus, intestinal pseudo-obstruction, or bowel obstruction — often supported by a gastric emptying study, endoscopy, imaging, or hospitalization records.
• Injury timing relative to medication use, and whether other causes were ruled out or disputed.
• State filing deadlines and individual procedural facts.

Severe, medically documented injuries — particularly those involving hospitalization — have been the focus of filed cases.

Case snapshot

The federal cases are centralized in MDL-3094 (In re: Glucagon-like Peptide-1 Receptor Agonists Products Liability Litigation) before Judge Karen S. Marston in the U.S. District Court for the Eastern District of Pennsylvania. The JPML created the MDL on February 2, 2024. As of June 1, 2026 it held 3,763 pending actions, with case counts updated monthly by the JPML.

Litigation updates

• June 2026: 3,763 cases pending in MDL-3094 and 110 in the separate NAION proceeding (MDL-3163) per the JPML's June 1 report; filings continue monthly.
• April 30, 2026: Case Management Order No. 32 set the amended expert and summary judgment schedule — briefing through August 7, 2026, and Rule 702 hearings September 10–18, 2026.
• 2025: The MDL grew past 1,500 cases; the court organized cross-cutting expert discovery and a streamlined docket (CMO No. 30, January 2026).
• February 2024: JPML centralized federal GLP-1 cases in the Eastern District of Pennsylvania, creating MDL-3094.

Current status

The litigation is active. Expert-admissibility (Rule 702) and summary judgment briefing are the current focus, with hearings set for September 10–18, 2026. Bellwether trial dates have not yet been set. New cases continue to be filed and transferred into the MDL, and no settlement program exists as of June 2026.

Who may be affected

People who used a GLP-1 medication and then experienced severe, documented gastrointestinal injury — especially gastroparesis confirmed by a gastric emptying study, or a bowel obstruction or ileus requiring emergency care — are the focus of current filings. Family members may have wrongful-death-related questions where an injury contributed to a death; those claims involve additional state-specific rules.

What happens before the first trials?

Under Case Management Order No. 32 (April 30, 2026), the parties complete Rule 702 expert-admissibility and summary judgment briefing by August 7, 2026, and the court holds Rule 702 hearings September 10–18, 2026. Those rulings decide which expert opinions and claims proceed — the gateway every mass tort passes through before bellwether trials are scheduled.

Bellwether trial dates have not yet been set. When they are, the schedule will appear in the court's case management orders, and this page will be updated.

Injuries alleged in filed cases

Gastroparesis — delayed gastric emptying that can cause persistent vomiting, malnutrition, and long-term complications. Ileus and bowel obstruction — intestinal blockage or paralysis that can require hospitalization or surgery. NAION — a sudden optic-nerve injury associated in some studies with semaglutide use, capable of causing permanent vision loss; NAION claims are consolidated in their own proceeding, MDL-3163 (110 pending actions as of June 1, 2026). Filed complaints also describe severe dehydration, aspiration events, and related complications.

Deadline considerations

GLP-1 claims follow state statutes of limitations, which commonly run two to three years from injury or discovery, depending on the state. Because GLP-1 injuries often develop during ongoing medication use, accrual and discovery-rule questions can be fact-intensive. State-specific pages below outline each state's general framework.

Sources and notes

Case counts on this page come from the JPML's monthly pending-MDL statistics (June 1, 2026 report). Court and assignment details come from Eastern District of Pennsylvania records. Drug approval and label information comes from FDA resources. This page summarizes allegations and public litigation data; it does not assert that any defendant is liable, and defendants dispute the claims.

Injuries involved

• Gastroparesis (delayed gastric emptying / stomach paralysis)
• Ileus and intestinal pseudo-obstruction
• Bowel obstruction
• Severe, persistent vomiting with complications
• NAION vision loss (separate proceeding — MDL-3163)

Evidence usually needed

• Prescription and pharmacy records
• Records showing dates and duration of GLP-1 use
• Gastroenterology diagnosis records
• Gastric emptying study results
• Hospitalization and emergency records
• Endoscopy or imaging reports
• Treatment and medication-change records

Timeline

Settlement status

No settlement program has been announced in the GLP-1 litigation as of June 2026. The court has scheduled Rule 702 (expert admissibility) hearings for September 10-18, 2026 under Case Management Order No. 32, with summary judgment briefing completing in August 2026; those rulings are the next events expected to shape settlement posture, and bellwether trial dates have not yet been set. Industry reporting has described very large potential exposure estimates if plaintiffs prevail, but estimates are not promises: no settlement, claim value, or outcome is guaranteed for any individual, and defendants continue to dispute the claims.

Deadline overview

Deadlines vary by state and may depend on diagnosis date, discovery date, exposure history, wrongful death issues, and other facts. A lawyer can evaluate how the relevant deadline rules may apply.

State-by-state guide links